文献速递临床试验与 GCP真实世界研究与卫生经济

津巴布韦社区ART续药组中稳定HIV患者3个月与6个月配药间隔的成本效果:实用性整群随机试验方案

The effectiveness and cost-effectiveness of 3- vs. 6-monthly dispensing of antiretroviral treatment (ART) for stable HIV patients in community ART-refill groups in Zimbabwe: study protocol for a pragmatic, cluster-randomized trial.
PubMed 文献 · Trials · 2018-01-29

该试验为津巴布韦30个整群(卫生机构及社区ART续药组)按1:1:1随机分为机构3个月配药(对照)、社区组内3个月配药、社区组内6个月配药三组,每臂1920名稳定成人ART患者。主要结局为入组12个月时存活且保留在 care 的比例,次要结局包括病毒学抑制比例及成本指标。

要点

  • 试验评估社区ART续药组内延长配药间隔(6个月 vs 3个月)的临床效果、成本效果与可接受性。
  • 主要结局为入组12个月时存活且保留在 care 的比例,采用非劣效性设计。
  • 次要结局包括12和24个月病毒学抑制比例及提供者成本、患者获取治疗成本。

核心结论

  • 该试验将评估在津巴布韦社区ART续药组中提供3个月与6个月配药间隔的临床效果、成本效果和可接受性,结果拟为国家及区域政策提供依据。

研究设计与样本

  • 实用性、三臂、平行、非盲、整群随机非劣效性试验,30个整群(卫生机构及相关社区ART续药组)按1:1:1 stratified randomization 分配。
  • 社区ART续药组由6-12名稳定患者组成,在社区聚会接收ART续药并相互支持。
  • 纳入基线病毒载量<1000 copies/ml的稳定成人ART患者,每臂1920名参与者。

主要发现

  • 主要结局为入组12个月时存活且保留在 care 的参与者比例。
  • 次要结局(12和24个月测量)包括病毒学抑制比例、每参与者平均提供者成本、每保留参与者提供者成本、每保留且病毒学抑制参与者成本及患者获取治疗的平均成本。
  • 定性研究将评估提供者和患者对社区ART续药组内延长配药间隔的可接受性,并评估干预可能带来的机构层面减负指标。

关键数值与推荐

  • 稳定成人ART患者基线病毒载量<1000 copies/ml可受邀参与,每臂1920名参与者。
  • 主要结局为入组12个月时存活且保留在 care 的比例。
  • 次要结局在12和24个月测量,包括病毒学抑制比例及各项成本指标。

临床怎么用

  • 该试验结果拟用于指导国家及区域政策,评估社区ART续药组中延长配药间隔对卫生系统和患者的潜在益处。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sub-Saharan Africa is the world region with the greatest number of people eligible to receive antiretroviral treatment (ART). Less frequent dispensing of ART and community-based ART-delivery models are potential strategies to reduce the load on overburdened healthcare facilities and reduce the barriers for patients to access treatment. However, no large-scale trials have been conducted investigating patient outcomes or evaluating the cost-effectiveness of extended ART-dispensing intervals within community ART-delivery models. This trial will assess the clinical effectiveness, cost-effectiveness and acceptability of providing ART refills on a 3 vs. a 6-monthly basis within community ART-refill groups (CARGs) for stable patients in Zimbabwe. METHODS: In this pragmatic, three-arm, parallel, unblinded, cluster-randomized non-inferiority trial, 30 clusters (healthcare facilities and associated CARGs) are allocated using stratified randomization in a 1:1:1 ratio to either (1) ART refills supplied 3-monthly from the health facility (control arm), (2) ART refills supplied 3-monthly within CARGs, or (3) ART refills supplied 6-monthly within CARGs. A CARG consists of 6-12 stable patients who meet in the community to receive ART refills and who provide support to one another. Stable adult ART patients with a baseline viral load < 1000 copies/ml will be invited to participate (1920 participants per arm). The primary outcome is the proportion of participants alive and retained in care 12 months after enrollment. Secondary outcomes (measured at 12 and 24 months) are the proportions achieving virological suppression, average provider cost per participant, provider cost per participant retained, cost per participant retained with virological suppression, and average patient-level costs to access treatment. Qualitative research will assess the acceptability of extended ART-dispensing intervals within CARGs to both providers and patients, and indicators of potential facility-level decongestion due to the interventions will be assessed. DISCUSSION: Cost-effective health system models that sustain high levels of patient retention are urgently needed to accommodate the large numbers of stable ART patients in sub-Saharan Africa. This will be the first trial to evaluate extended ART-dispensing intervals within a community-based ART distribution model, and results are intended to inform national and regional policy regarding their potential benefits to both the healthcare system and patients. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03238846 . Registered on 27 July 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Fatti G, Ngorima-Mabhena N, Chirowa F, et al. The effectiveness and cost-effectiveness of 3- vs. 6-monthly dispensing of antiretroviral treatment (ART) for stable HIV patients in community ART-refill groups in Zimbabwe: study protocol for a pragmatic, cluster-randomized trial. Trials. 2018. PMID: 29378662. doi:10.1186/s13063-018-2469-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。